Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › FDA Issues Warning Letter to Becton Dickinson Over Facility Violations

FDA Issues Warning Letter to Becton Dickinson Over Facility Violations

Jan 11, 2018
|
staff reporter

This article has been updated to include a response from Becton Dickinson.

NEW YORK (360DX) – The US Food and Drug Administration today issued a warning letter to Becton Dickinson, outlining a number of violations of federal law related to the company's Vacutainer blood collection tubes, including changes it made to the tubes and its failure to investigate complaints about their performance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

  2. Dx Developers Hedge on SARS-Cov-2 Rapid Antigen Tests, Citing Conflicting FDA Messages

    Premium

  3. FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

  4. Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

  5. Ortho Clinical Diagnostics Nabs CE Mark for Semi-Quantitative SARS-CoV-2 Antibody Tests

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.